Goserelin
Highest phase reached
Approved
Drug type
Protein
First approval year
1989
- First approval year
- 1989
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Goserelin
- Molecular weight
- 1,269.43
- Structure (SMILES)
- CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
- 1 5 oxo l prolyl l histidyl l tryptophyl l seryl l tyrosyl o tert butyl d seryl l leucyl l arginyl l prolyl semicarbazide
- 1-(5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-O-TERT-BUTYL-D-SERYL-L-LEUCYL-L-ARGINYL-L-PROLYL)SEMICARBAZIDE
- goserelin
- Goserelin
- GOSERELIN [EP MONOGRAPH]
- GOSERELIN [HSDB]
- goserelin [INN]
- GOSERELIN [MART.]
- GOSERELIN [MI]
- GOSERELIN [USAN]
- Goserelin [WHO-DD]
- goserelin ep monograph
- goserelin hsdb
- goserelin inn
- goserelin mart
- goserelin mi
- goserelin usan
- goserelin who dd
- goserelina
- Goserelina
- gosereline
- Gosereline
- ici 118 630
- ICI 118,630
- ici 118630
And 3 more, listed on the interactive page.
- ATC classification codes
- L02AE03
Sources for recorded values
- CAS registry numbers
- 65807-02-5
- ChEMBL ID
- CHEMBL1201247
- InChIKey
- BLCLNMBMMGCOAS-URPVMXJPSA-N
- PubChem compound IDs
- 5311128
- FDA ingredient codes (UNII)
- 0F65R8P09N
- 50610
- 203146
- Applicant
- TERSERA
- Approval date
- 29 Dec 1989
- Application number
- NDA019726
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- goserelin
- Type
- Peptide
- Drug name stem
- -relin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Mechanisms of action
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- GnRH1 receptor
- Gene symbol
- GNRHR
- Protein identifier
- P30968
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
- Action type
- Agonist
- Target
- Gonadotropin-releasing hormone receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- GNRHR
- Protein identifier
- P30968
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Hodgkin Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Metabolic Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000195
- Subject identifier
- D024821
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Infertility
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Carcinoma, Lobular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000553
- Subject identifier
- D018275
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Leiomyoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000731
- Subject identifier
- D007889
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Adenomyosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001757
- Subject identifier
- D062788
- Condition
- Primary Ovarian Insufficiency
- Highest recorded phase
- 2
- Condition identifier
- HP:0008209
- Subject identifier
- D016649
- Condition
- Salivary Gland Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004669
- Subject identifier
- D012468
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Condition identifier
- EFO_0000731
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008008
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009003
- Highest recorded phase
- 2
- Condition identifier
- HP_0000131
- Highest recorded phase
- 3
- Condition identifier
- HP_0000855
- Highest recorded phase
- 2
- Condition identifier
- HP_0008209
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000521
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002113
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004669
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004989
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005051
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005082
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005133
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 2
And 11 more, listed on the interactive page.
- Event
- abdominal lymphadenopathy
- Reports
- 26
- Reporting signal score
- 107.418
- Event
- adnexa uteri mass
- Reports
- 10
- Reporting signal score
- 42.0788
- Event
- arterial injury
- Reports
- 10
- Reporting signal score
- 34.1699
- Event
- ascites
- Reports
- 36
- Reporting signal score
- 40.1539
- Event
- blood testosterone increased
- Reports
- 12
- Reporting signal score
- 34.2239
- Event
- bone lesion
- Reports
- 22
- Reporting signal score
- 55.8547
- Event
- breast cancer
- Reports
- 93
- Reporting signal score
- 171.084
- Event
- breast cancer metastatic
- Reports
- 75
- Reporting signal score
- 245.713
- Event
- breast cancer recurrent
- Reports
- 16
- Reporting signal score
- 39.4196
- Event
- carbohydrate antigen 15-3 increased
- Reports
- 10
- Reporting signal score
- 35.2477
- Event
- carcinoid tumour pulmonary
- Reports
- 13
- Reporting signal score
- 59.6145
- Event
- central nervous system lesion
- Reports
- 22
- Reporting signal score
- 33.9997
- Event
- circumstance or information capable of leading to device use error
- Reports
- 14
- Reporting signal score
- 59.6325
- Event
- cyp3a4 polymorphism
- Reports
- 8
- Reporting signal score
- 52.7301
- Event
- device safety feature issue
- Reports
- 8
- Reporting signal score
- 41.4062
- Event
- disease progression
- Reports
- 91
- Reporting signal score
- 81.8334
- Event
- expulsion of medication
- Reports
- 24
- Reporting signal score
- 129.699
- Event
- hot flush
- Reports
- 101
- Reporting signal score
- 174.242
- Event
- interstitial lung disease
- Reports
- 67
- Reporting signal score
- 74.9696
- Event
- jaundice
- Reports
- 37
- Reporting signal score
- 35.2953
- Event
- lymphadenopathy
- Reports
- 37
- Reporting signal score
- 36.685
- Event
- malignant neoplasm progression
- Reports
- 390
- Reporting signal score
- 1,031.87
- Event
- metastases to bone
- Reports
- 168
- Reporting signal score
- 557.05
- Event
- metastases to central nervous system
- Reports
- 31
- Reporting signal score
- 58.7844
- Event
- metastases to liver
- Reports
- 126
- Reporting signal score
- 383.584
And 16 more, listed on the interactive page.
- NCT00002633
- NCT00002889
- NCT00003653
- NCT00004124
- NCT00004635
- NCT00028769
- NCT00223171
- NCT00303784
- NCT00349557
- NCT00388804
- NCT00482807
- NCT00631527
- NCT00651326
- NCT00669162
- NCT00769795
- NCT00771017
- NCT00831233
- NCT00833248
- NCT00841113
- NCT00884273
- NCT00936390
- NCT01252693
- NCT01377389
- NCT01496131
- NCT01744366
And 79 more, listed on the interactive page.
- Dose
- 3.6 mg
- Route
- Subcutaneous
- How often
- Every 28 days
- Calculated partition coefficient (XLogP)
- -1.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 91
- Molecular formula
- C59H84N18O14
- Monoisotopic mass
- 1268.64143943
- Natural product
- Yes
- Recorded assays
- 117
- Active assays
- 1
Active assay types
- Other
- Antineoplastic Agents, Hormonal
Related records
Trials (129)
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
- Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
- Adaptions and Resiliency to Multi-Stressor OpeRations
- Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
- Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
- Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
- Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
- Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
Approved for (1)
In development for (28)
- Adenomyoma Phase 2
- Adenomyosis Phase 2
- Breast cancer Phase 3
- Breast carcinoma Phase 3
- Breast neoplasm Phase 3
- Cancer Phase 2
- Estrogen-receptor positive breast cancer Phase 2
- Fallopian tube carcinoma Phase 2
- Hodgkins lymphoma Phase 2
- Infertility disorder Phase 3
- Invasive lobular breast carcinoma Phase 2
- Malignant epithelial tumor of ovary Phase 2
- Metabolic syndrome X Phase 2
- Metastatic prostate carcinoma Phase 3
- Ovarian carcinoma Phase 2
- Ovarian dysfunction Phase 2
- Peritoneal carcinoma Phase 2
- Premature ovarian failure 1 Phase 2
- Primary ovarian failure Phase 2
- Prostate adenocarcinoma Phase 3
Other linked conditions (1)
Targets (1)
- GNRHR Gonadotropin-releasing hormone receptor agonist